太原痔疮自己怎么治(太原肛门坠) (今日更新中)

Thousands of elevator permits in San Diego County are out of date, according to the Department of Industrial Relations. In San Diego and Imperial Counties, a DIR spokesperson said there are 12,541 elevator permits issued. Of those, 6,932 are expired. DIR spokesperson Frank Polizzi said there is no penalty for expired permits, “but a unit should not be running if it has been tagged out of service for a maintenance/safety reason.”Team 10 visited several elevators in downtown San Diego and found there was no permit displayed in the elevator at all—including an elevator at Horton Plaza and one operated by the City of San Diego. Polizzi said there are other reasons a displayed permit could be expired, besides the elevator being out of compliance. The owner could be waiting for a Cal/OSHA permit inspection or they have not posted the most updated permit. 868

This is misleading. We are complying with the Judge’s order. The Grand Jury audio recording is more than 20 hrs long, & we filed a motion to request additional time, if the court permits it, to redact personally identifiable information of witnesses (addresses and phone numbers). pic.twitter.com/cvNJc5AZpa— Attorney General Daniel Cameron (@kyoag) September 30, 2020 385

Too few new antibiotics are under development to combat the threat of multidrug-resistant infections, according to a new World Health Organization report published Tuesday. Adding to the concern: It is likely that the speed of increasing resistance will outpace the slow drug development process.As of May, a total of 51 antibiotics and 11 biologicals -- medical products often made from natural sources -- are being developed, the new report said."The idea is that biologicals could replace use of antibiotics, which could help in overcoming the resistance problem," Peter Beyer, an author of the report and senior adviser to the WHO's Department of Essential Medicines and Health Products, wrote in an email.Seemingly, this large number of potential new drugs should suffice, yet it is not nearly enough.First, just 33 of the antibiotics in the pipeline target priority pathogens. This year, the WHO published a list of a dozen "priority pathogens": 12 separate families of antibiotic-resistant bacteria that pose the greatest threat to human health.Among the priority pathogens is a drug-resistant tuberculosis, which kills about 250,000 people around the world each year, and a variety of multidrug resistant strains -- Acinetobacter, Pseudomonas and various Enterobacteriaceae -- which are responsible for infections in hospitals and nursing homes and among patients whose care requires ventilators and catheters.Of the 33 potential medicines for treating priority bug infections, only eight are innovative treatments. The other 25 are simple modifications of existing families of antibiotics. At best, then, the 25 will serve as short-term solutions since it is expected bacteria will quickly adapt to and resist these new (though somewhat familiar) drugs, according to the WHO."It is difficult to speculate why companies develop specific new medicines," Beyer noted. "But in general many new treatments do not necessarily constitute advances over existing treatments."TB infections require a combination of at least three antibiotics, according to the new report, yet only seven of the new TB medicines are even in clinical trials. Soon, there will be a serious lack of treatment options for this infection, the report warns.The same is true for gram-negative pathogens, which can cause severe, often deadly infections typically in hospitals and nursing homes.Gram-negative bacteria have more complex cell walls than gram-positive, explained Beyer. "In a nutshell, it is more complex to develop a novel antibiotic that can penetrate the complex gram-negative cell wall and stay inside the bacterium," he wrote.Finally, the WHO sees too few oral antibiotics being developed. These are necessary "to target the critical priority pathogens (and) be accessible in low- and middle-income countries," Beyer noted.To address the problem of developing new antibiotics, the WHO and the Drugs for Neglected Diseases Initiative set up the Global Antibiotic Research and Development Partnership. However, new drugs alone cannot combat the threat of antimicrobial resistance. The WHO is also working to improve infection prevention and control while developing guidance for the responsible use of antibiotics."Always seek medical advice before taking antibiotics and then always follow the advice of the health-care professional," Beyer noted.The new report is a "fantastic (and very useful!) summary" of the antibiotic situation, wrote Bill Hanage, an associate professor of epidemiology at Harvard T.H. Chan School of Public Health, in an email. Hanage, who has also published studies of antibiotic resistance, was not involved in the new report.Although the risk of getting a completely resistant infection is low in the United States, about 2 million people each year become infected with "resistant enough" bacteria that are harder to treat, Hanage said. And every year, more than 20,000 people die of these infections."More resistant infections don't just mean you or someone you care about is more likely to die from one, they also mean healthcare will get even more expensive," Hanage said. "Many of the procedures we take for granted in medicine, from cancer treatments to surgeries, depend on our ability to handle infections that happen in the course of treatment."The number of new drugs in development is simply not enough, he said."The great majority will not make it into the hands of doctors or your treatment," Hanage wrote. "As the report states, for drugs to be used in humans they have to pass 3 hurdles, the phase 1, 2 and 3 trials. Drugs entering that pipeline have just a 14% chance of getting all the way through to be used in humans." 4676

There's a new warning about makeup. A watchdog group says it has found asbestos in several products, sold in a store targeted to teens and young girls. What do you think of when you hear the word asbestos?“I think of like commercials like where your loved one has been exposed to asbestos and you die,” one woman says. “I'm like, 'Oh my God,' it's terrible.”Another woman said, “Like in a house that's like shut down forever” she says. “There's asbestos in a house.”You don't usually think of makeup.Danny Katz with U.S. PIRG, a consumer watchdog group said it tested more than a dozen make up products and found "high levels of asbestos" in three. They're all sold at Claire's, a store with products aimed toward girls and young women.“It's completely unacceptable to have asbestos in these products,” Katz says. “Asbestos if you inhale it or ingested it can lead to lung cancer it can lead to mesothelioma, which is cancer of the internal organs, and if you apply it over skin over time it can also increase the risk of skin cancer."Asbestos is a naturally occurring mineral that can be found in talc, a common product in many makeup products. But Katz says it's a company's responsibility to make sure the talc it uses hasn't been contaminated.“We need Claire's to remove these products from the shelves and we need them to figure out how asbestos got in their products to begin with,” Katz says. “We need Congress and the FDA to take action. We need to ban asbestos from beauty care products and makeup.”Right now, Katz and U.S. PIRG are urging us to avoid products with talc until federal laws change.It's not the first time Claire's has come under scrutiny for this. Just four months ago, Claire's pulled some items after independent lab tests found evidence of asbestos, then said its own initial testing found no problems.Regarding these latest allegations, Claire's released a statement saying,  1952

TORONTO (AP) -- The Toronto Raptors selected 6-foot-1 San Diego State guard Malachi Flynn 29th overall in the NBA draft, and 6-foot-5 Nevada guard Jalen Harris 59th.The Raptors face some uncertainty at point guard. Toronto hopes to re-sign free agent Fred VanVleet, while six-time All-Star Kyle Lowry, now 34, has one year remaining on his contract.Flynn began his college career with two seasons at Washington State before playing his junior season with the Aztecs.Flynn averaged 15.8 points per game in his final season with the Cougars, and boosted that to 17.6 points as a junior at SDSU, adding 5.1 assists and 4.5 rebounds.The 22-year-old Flynn was named the 2019-20 Mountain West Player of the Year and the conference's Defensive Player of the Year. 764

来源：资阳报